Johnson MW - Search Results

1

Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities.

Yaden DB, Johnson MW, Griffiths RR, Doss MK, Garcia-Romeu A, Nayak S, Gukasyan N, Mathur BN, Barrett FS. Yaden DB, et al. Among authors: johnson mw. Int J Neuropsychopharmacol. 2021 Aug 20;24(8):615-623. doi: 10.1093/ijnp/pyab026. Int J Neuropsychopharmacol. 2021. PMID: 33987652 Free PMC article. Review.

2

Developing evidence-based clinicians.

Johnson M, Griffiths R. Johnson M, et al. Int J Nurs Pract. 2001 Apr;7(2):109-18. doi: 10.1046/j.1440-172x.2001.00285.x. Int J Nurs Pract. 2001. PMID: 11811313 Review.

3

Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds.

Griffiths RR, Johnson MW. Griffiths RR, et al. Among authors: johnson mw. J Clin Psychiatry. 2005;66 Suppl 9:31-41. J Clin Psychiatry. 2005. PMID: 16336040

4

Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.

Johnson MW, Suess PE, Griffiths RR. Johnson MW, et al. Arch Gen Psychiatry. 2006 Oct;63(10):1149-57. doi: 10.1001/archpsyc.63.10.1149. Arch Gen Psychiatry. 2006. PMID: 17015817

5

Effects of oral caffeine pretreatment on response to intravenous nicotine and cocaine.

Johnson MW, Strain EC, Griffiths RR. Johnson MW, et al. Exp Clin Psychopharmacol. 2010 Aug;18(4):305-15. doi: 10.1037/a0020509. Exp Clin Psychopharmacol. 2010. PMID: 20695686 Free PMC article. Clinical Trial.

6

Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum.

Johnson MW, MacLean KA, Reissig CJ, Prisinzano TE, Griffiths RR. Johnson MW, et al. Drug Alcohol Depend. 2011 May 1;115(1-2):150-5. doi: 10.1016/j.drugalcdep.2010.11.005. Epub 2010 Dec 4. Drug Alcohol Depend. 2011. PMID: 21131142 Free PMC article. Clinical Trial.

7

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.

Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Griffiths RR, et al. Among authors: johnson mw. Psychopharmacology (Berl). 2011 Dec;218(4):649-65. doi: 10.1007/s00213-011-2358-5. Epub 2011 Jun 15. Psychopharmacology (Berl). 2011. PMID: 21674151 Free PMC article. Clinical Trial.

8

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.

MacLean KA, Johnson MW, Griffiths RR. MacLean KA, et al. Among authors: johnson mw. J Psychopharmacol. 2011 Nov;25(11):1453-61. doi: 10.1177/0269881111420188. Epub 2011 Sep 28. J Psychopharmacol. 2011. PMID: 21956378 Free PMC article.

9

Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.

Johnson MW, Sewell RA, Griffiths RR. Johnson MW, et al. Drug Alcohol Depend. 2012 Jun 1;123(1-3):132-40. doi: 10.1016/j.drugalcdep.2011.10.029. Epub 2011 Nov 29. Drug Alcohol Depend. 2012. PMID: 22129843 Free PMC article. Clinical Trial.

10

High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens.

Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Griffiths RR. Reissig CJ, et al. Among authors: johnson mw. Psychopharmacology (Berl). 2012 Sep;223(1):1-15. doi: 10.1007/s00213-012-2680-6. Epub 2012 Apr 13. Psychopharmacology (Berl). 2012. PMID: 22526529 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

631 results

Search Page

Filters